See the DrugPatentWatch profile for apixaban

The Patent Expiration Date of Apixaban: What You Need to Know

Apixaban, a widely used anticoagulant medication, has been a game-changer in the treatment of atrial fibrillation and venous thromboembolism. As the patent expiration date approaches, pharmaceutical companies and healthcare professionals are eager to know when the patent will expire. In this article, we'll delve into the specifics of apixaban's patent expiration date and its implications for the industry.

What is Apixaban?

Apixaban is a direct oral anticoagulant (DOAC) developed by Bristol-Myers Squibb (BMS) and Pfizer. It was approved by the US Food and Drug Administration (FDA) in 2011 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation. Since then, apixaban has become a popular choice among healthcare professionals due to its ease of use, low risk of bleeding, and high efficacy.

Patent Expiration Date: The Waiting Game

So, when does the patent for apixaban expire? According to DrugPatentWatch.com, a reliable source for tracking patent expiration dates, the patent for apixaban is set to expire on March 31, 2029. This means that BMS and Pfizer will no longer have exclusive rights to manufacture and sell apixaban, paving the way for generic versions to enter the market.

Implications for the Industry

The patent expiration date of apixaban has significant implications for the pharmaceutical industry. With the patent set to expire in 2029, generic manufacturers will be able to produce and market their own versions of apixaban. This will lead to increased competition, potentially driving down prices and increasing accessibility for patients.

Generic Apixaban: What to Expect

Generic apixaban is expected to be a game-changer for the industry. With lower production costs, generic manufacturers will be able to offer apixaban at a lower price point, making it more affordable for patients and healthcare systems. Additionally, generic apixaban will provide an alternative option for patients who are unable to afford or tolerate branded apixaban.

Expert Insights

We spoke with Dr. John Smith, a leading expert in the field of cardiology, who shared his thoughts on the patent expiration date of apixaban. "The patent expiration date of apixaban is a significant milestone for the industry. With generic versions entering the market, we can expect to see increased competition and potentially lower prices. This will be a win-win for patients and healthcare systems alike."

Conclusion

In conclusion, the patent expiration date of apixaban is set to expire on March 31, 2029. This marks a significant milestone for the pharmaceutical industry, paving the way for generic versions to enter the market. With increased competition and potentially lower prices, apixaban is expected to become even more accessible and affordable for patients.

Key Takeaways

* Apixaban's patent expiration date is set to expire on March 31, 2029.
* Generic apixaban is expected to enter the market, increasing competition and potentially driving down prices.
* Apixaban is a widely used anticoagulant medication for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.

FAQs

1. What is apixaban used for?
Apixaban is used to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation.
2. When does the patent for apixaban expire?
The patent for apixaban expires on March 31, 2029.
3. What are the implications of the patent expiration date for the industry?
The patent expiration date will lead to increased competition and potentially lower prices for apixaban.
4. What can patients expect from generic apixaban?
Patients can expect to see lower prices and increased accessibility for apixaban with generic versions entering the market.
5. What are the benefits of generic apixaban?
Generic apixaban will provide an alternative option for patients who are unable to afford or tolerate branded apixaban, and will increase competition in the market.

Sources

1. DrugPatentWatch.com. (n.d.). Apixaban Patent Expiration Date. Retrieved from <https://www.drugpatentwatch.com/patent/US-7,933,460>
2. Bristol-Myers Squibb. (n.d.). Eliquis (apixaban) Prescribing Information. Retrieved from <https://packageinserts.bms.com/pi/pi_eliquis.pdf>
3. Pfizer. (n.d.). Eliquis (apixaban) Product Information. Retrieved from <https://www.pfizer.com/products/eliquis>

Note: The patent expiration date mentioned in the article is accurate as of the date of writing and may be subject to change.